

**Amendments to the Claims:**

Please cancel claims 1-28, and add new claims 36-41. This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-28 (canceled)

29 (previously presented): Fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety that is a nucleic acid, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

30 (previously presented): The conjugate of claim 29, wherein said substance capturing moiety is an antibody, a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

31 (previously presented): The conjugate of claim 29, further comprising a pharmaceutically active substance.

32 (previously presented): The conjugate of claim 31, wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, wound-healing substances, and imaging agents.

33 (previously presented): The conjugate of claim 29, wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

34 (currently amended): Fibrin/fibrinogen-binding conjugate comprising

a fibrin/fibrinogen-binding moiety selected from the group consisting of **thrombin**, fibronectin, bacterial fibrinogen binding proteins, integrins, and moieties derived from any member of this group,

a substance capturing moiety that is an antibody or a part thereof which specifically recognizes a pharmaceutically active substance, and

the pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

35 (currently amended): Fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety selected from the group consisting of **thrombin**, fibronectin, bacterial fibrinogen binding proteins, integrins, and moieties derived from any member of this group,

a substance capturing moiety that is an antibody or a part thereof which specifically recognizes a pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

36 (new): The conjugate of claim 34, wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, and imaging agents.

37 (new): The conjugate of claim 34, wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

38 (new): The conjugate of claim 34, wherein said pharmaceutically active substance is a wound healing substance.

39 (new): The conjugate of claim 35 wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

40 (new): The conjugate of claim 35 wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, and imaging agents.

41 (new): The conjugate of claim 35, wherein said pharmaceutically active substance is a wound healing substance.